Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
A gene signature predicts sensitivity to the partial CD40 agonist, dacetuzumab (SGN-40), in patients with diffuse large B-cell lymphoma Burington, B., Advani, R., Shi, X., Yue, P., Lau, J., Yu, S., Januario, T., de Vos, S., Ansell, S., Forero-Torres, A., Ebens, A., Whiting, N., Dornan, D. AMER ASSOC CANCER RESEARCH. 2009
View details for Web of Science ID 000209701805315